Copyright
©2010 Baishideng.
World J Gastroenterol. Jan 7, 2010; 16(1): 89-97
Published online Jan 7, 2010. doi: 10.3748/wjg.v16.i1.89
Published online Jan 7, 2010. doi: 10.3748/wjg.v16.i1.89
Table 1 Basic demographic, virological, and clinical features of the 100 patients whose data were used as selection data
SVR | non-SVR | P value | |
Number (%) | 54 (54.0) | 46 | |
Gender (%) | |||
Male | 43 (60.6) | 28 | 0.038 |
Female | 9 (34.6) | 18 | |
Age | |||
Median | 53 | 57 | 0.0098 |
Range | 18-72 | 37-77 | |
Weight (kg) | |||
Median | 65.1 | 60 | 0.138 |
Range | 42.5-90.5 | 43.9-86.0 | |
BMI (kg/m2) | |||
Median | 23.5 | 22.9 | 0.834 |
Range | 17.5-31.8 | 18.2-31.2 | |
Previous + treatment | 22 | 19 | 1.000 |
HCV RNA (KIU/mL) | |||
Median | 1889 | 2263 | 0.554 |
Range | 140 to < 5000 | 150 to < 5000 | |
RBC (× 10-4/mL) | |||
Median | 469 | 452 | 0.0041 |
Range | 319-621 | 354-552 | |
Hb (g/dL) | |||
Median | 15.0 | 14.1 | 0.0059 |
Range | 10.9-17.7 | 11.3-17.2 | |
PLT (× 10-3/mL) | |||
Median | 172 | 159 | 0.039 |
Range | 84-292 | 62-270 | |
WBC (/mL) | |||
Median | 5000 | 4850 | 0.256 |
Range | 3270-8900 | 2300-9200 | |
NC (/mL) | |||
Median | 2550 | 2549 | 0.978 |
Range | 1066-4231 | 1184-5626 | |
AST (IU/L) | |||
Median | 54 | 50 | 0.898 |
Range | 22-156 | 24-241 | |
ALT (IU/L) | |||
Median | 76 | 55 | 0.027 |
Range | 36-311 | 15-278 | |
PEG-IFN dose (48 wk) (μg/kg per day) | |||
Median | 1.43 | 1.32 | 0.0043 |
Range | 0.68-1.82 | 0.52-1.82 | |
RBV dose (48 wk) (mg/kg per day) | |||
Median | 10.83 | 8.39 | 0.0002 |
Range | 3.42-14.55 | 2.75-12.64 |
Table 2 Logistic regression analysis of independent predictive factors for sustained virological response
Variables | Odds ratio | 95% CI | P value |
At pretreatment | |||
RBC (× 104) (0 wk) | 1.011 | 1.002-1.021 | 0.024 |
PLT (× 103) (0 wk) | 1.085 | 0.986-1.193 | 0.095 |
log (ALT 0 wk) | 3.509 | 0.727-16.934 | 0.118 |
At week 4 | |||
Age | 0.941 | 0.885-1.000 | 0.051 |
log (ALT 0 wk) | 27.090 | 1.891-388.001 | 0.015 |
RVR +/- | 6.543 | 1.766-24.243 | 0.0049 |
log (AST 0 wk) | 0.036 | 0.001-0.886 | 0.042 |
At week 12 | |||
log (ALT 0 wk) | 39.331 | 2.648-584.144 | 0.0076 |
RVR +/- | 3.015 | 0.694-13.100 | 0.141 |
EVR +/- | 8.340 | 1.728-40.265 | 0.0083 |
WBC (4 wk) | 1.001 | 1.000-1.002 | 0.035 |
log (AST 12 wk) | 0.049 | 0.002-1.037 | 0.053 |
RBV dose (12 wk) | 1.519 | 1.010-2.284 | 0.045 |
At week 24 | |||
log (ALT 0 wk) | 68.688 | 3.669 to < 999.999 | 0.0047 |
RVR +/- | 3.329 | 0.819-13.529 | 0.093 |
EVR +/- | 31.775 | 2.840-355.460 | 0.0050 |
WBC (4 wk) | 1.001 | 1.000-1.002 | 0.044 |
log (AST 12 wk) | 0.036 | 0.001-0.918 | 0.044 |
RBV dose (12 wk) | 1.607 | 1.021-2.528 | 0.040 |
Table 3 The median predictive values for sustained virological response (SVR) rates calculated using our formulae at pretreatment and weeks 4, 12 and 24
Median (range) | Patients who attained SVR | Patients with non-SVR | P value |
Pretreatment | 0.545 (0.286-0.926) | 0.507 (0.108-0.945) | 0.514 |
At week 4 | 0.661 (0.139-0.998) | 0.251 (0.056-0.688) | 0.000 |
At week 12 | 0.589 (0.079-0.994) | 0.146 (0.001-0.952) | 0.000 |
At week 24 | 0.656 (0.038-0.996) | 0.026 (0.000-0.949) | 0.000 |
Table 4 Positive and negative predictive values calculated by the formula constructed with data at week 48
Cut-off point | PPV (%) | NPV (%) | P value |
0.2 | 65.9 | 100 | < 0.00001 |
0.3 | 66.7 | 96.7 | < 0.00001 |
0.4 | 66.7 | 86.1 | < 0.00001 |
0.5 | 68.8 | 82.5 | 0.000013 |
0.6 | 71.4 | 79.5 | 0.000024 |
0.7 | 77.3 | 76.0 | 0.000048 |
0.8 | 80.0 | 70.2 | 0.00074 |
- Citation: Saito H, Ebinuma H, Ojiro K, Wakabayashi K, Inoue M, Tada S, Hibi T. On-treatment predictions of success in peg-interferon/ribavirin treatment using a novel formula. World J Gastroenterol 2010; 16(1): 89-97
- URL: https://www.wjgnet.com/1007-9327/full/v16/i1/89.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i1.89